| Literature DB >> 30568044 |
Kendall M Lawrence1, Samson Hennessy-Strahs2, Patrick E McGovern1, Ali Y Mejaddam1, Avery C Rossidis1, Heron D Baumgarten1, Esha Bansal2, Maryann Villeda2, Jiancheng Han1, Zhongshan Gou1, Sheng Zhao1, Jack Rychik3, William H Peranteau1, Marcus G Davey1, Alan W Flake1, J William Gaynor4, Carlo R Bartoli2.
Abstract
In utero hypoxia is a major cause of neonatal morbidity and mortality and predisposes to adult cardiovascular disease. No therapies exist to correct fetal hypoxia. In a new ex utero fetal support system, we tested the hypothesis that hypoxemic support of the fetus impairs myocardial development, whereas normoxic support allows normal myocardial development. Preterm fetal lambs were connected via umbilical vessels to a low-resistance oxygenator and placed in a sterile-fluid environment. Control normoxic fetuses received normal fetal oxygenation, and hypoxemic fetuses received subphysiologic oxygenation. Fetuses with normal in utero development served as normal controls. Hypoxemic fetuses exhibited decreased maximum cardiac output in both ventricles, diastolic function, myocyte and myocyte nuclear size, and increased myocardial capillary density versus control normoxic fetuses. There were no differences between control normoxic fetuses in the fetal support system and normal in utero controls. Chronic fetal hypoxemia resulted in significant abnormalities in myocyte architecture and myocardial capillary density as well as systolic and diastolic cardiac function, whereas control fetuses showed no differences. This ex utero fetal support system has potential to become a significant research tool and novel therapy to correct fetal hypoxia.Entities:
Keywords: Cardiovascular disease; Fertility; Reproductive Biology; Therapeutics; hypoxia
Mesh:
Substances:
Year: 2018 PMID: 30568044 PMCID: PMC6338387 DOI: 10.1172/jci.insight.124338
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708